SPDE Speedus Corp (CE)

PRINCETON, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Zargis Medical Corp., founded by Siemens Corporate Research and Speedus Corp (NASDAQ:SPDE), today announced the response from a panel of primary care physicians assembled to evaluate a prototype computer-aided auscultation system. After a thorough review of the prototype system, all seven panelists agreed that it would improve their referral accuracy of patients with heart murmurs. In addition, six members of the panel reported that the prototype system and the results it provided were "very easy to understand and use." This is considered important because it implies the system would integrate well into the busy workflow of the typical primary care physician's office. "The field of computer-aided auscultation continues to gain momentum with healthcare decision makers," stated Zargis CEO John Kallassy. "This kind of clinical feedback from board certified physicians further supports Zargis as we pursue commercialization opportunities and potential strategic alliances." Input gathered from this panel helps validate Zargis' ongoing R&D efforts, which are focused on developing potential enhancements to the Zargis Acoustic Cardioscan(TM) (ZAC) system-the Company's existing, FDA-authorized device. Zargis may incorporate new features from the prototype evaluated by the physicians into ZAC, pending authorization from the FDA. The new features could be added in time for the commercial introduction of ZAC. About Zargis Medical Corp. Zargis Medical Corp. develops advanced diagnostic decision support products and services for primary care physicians, pediatricians, cardiologists and other healthcare professionals. Zargis was formed in 2001 when Siemens Corporate Research, a division of Siemens AG (NYSE:SI), and Speedus Corp. co-invested to develop and market an advanced acoustic technology designed to detect heart abnormalities identified through analysis of heart sounds. About ZAC Zargis has developed ZAC, the first and only FDA-authorized computer- assisted medical device to support physicians in analyzing heart sounds for the identification of suspected murmurs. The non-invasive device is easy to use, portable, and takes just minutes to perform. ZAC implements voice-guided protocol and a graphical user interface while maintaining an efficient physician workflow. The system provides a summary of findings in terms that are readily understood by physicians and offers an additional range of quantitative auscultatory information that cannot be obtained through listening alone. As a result, ZAC enhances auscultation-a procedure that has been universally employed through a stethoscope for nearly two hundred years. About Speedus Corp. Speedus Corp. is a holding company with controlling interests in Zargis Medical Corp. and F&B Gudtfood Holdings, Inc. Speedus Corp. also owns broadband intellectual property and controls licensed wireless frequencies. For additional information about Zargis Medical or Speedus Corp., contact Peter Hodge at 203.829.1348 or , or visit the following Web sites: http://www.zargis.com/ and http://www.speedus.com/. Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts. DATASOURCE: Zargis Medical Corp. CONTACT: Peter Hodge, +1-888-773-3669 ext. 23, Web site: http://www.speedus.com/ http://www.zargis.com/

Copyright